Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: A Production Assistant for Cell Therapy (PACT) translational application

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Sun, Jiali ^a,b   Huye, Leslie E ^a   Lapteva, Natalia ^a,b   Mamonkin, Maksim ^a   Hiregange, Manasa ^a   Ballard, Brandon ^a   Dakhova, Olga ^a   Raghavan, Darshana ^a   Durett, April G ^a   Perna, Serena K ^a   Omer, Bilal ^a   Rollins, Lisa A ^a   Leen, Ann M ^a,b   Vera, Juan F ^a,b   Dotti, Gianpietro ^a,b   Gee, Adrian P ^a,b   Brenner, Malcolm K ^a,b   Myers, Douglas G ^c   Rooney, Cliona M ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Chimeric antigen receptor; Clinical grade T cell manufacture; Virus specific T cells

Indexed keywords

ALPHA2 INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; DISIALOGANGLIOSIDE; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; L SELECTIN; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL ASSAY; CELL DIFFERENTIATION; CELL EXPANSION; CELL LINE; CELL PROLIFERATION; CELL THERAPY; CENTRIFUGATION; CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; CYTOMEGALOVIRUS; CYTOTOXICITY ASSAY; DNA EXTRACTION; EFLUOR DILUTION ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MEMORY; NEUROBLASTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS INFECTION; VIRUS SPECIFIC T CELL;

EID: 84977120224     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0049-1     Document Type: Article

References (29)

1. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-70. 10.1038/nm.1882, 18978797.
2. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6. 10.1182/blood-2011-05-354449, 21984804.
3. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-34. 10.1084/jem.192.7.1027, 11015443.
4. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-5. 14559843.
5. Tu E, Chia PZ, Chen W. TGFbeta in T cell biology and tumor immunity: Angel or devil? Cytokine Growth Factor Rev. 2014..
6. Heslop HE, Leen AM. T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program 2013, 2013:342-7. 10.1182/asheducation-2013.1.342, 24319202.
7. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122:2965-73. 10.1182/blood-2013-06-506741, 24030379.
8. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012, 20:1622-32. 10.1038/mt.2012.130, 22801446.
9. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013, 21:2113-21. 10.1038/mt.2013.151, 23783429.
10. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014, 6:242ra83. 10.1126/scitranslmed.3008825, 24964991.
11. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-6. 10.1038/nm1475, 16998485.
12. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008, 31:665-74. 10.1097/CJI.0b013e318181b4bd, 18600178.
13. Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, et al. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant 2013, 19:1480-92. 10.1016/j.bbmt.2013.07.015, 23891747.
14. Rossig C, Bar A, Pscherer S, Altvater B, Pule M, Rooney CM, et al. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother 2006, 29:21-31. 10.1097/01.cji.0000175492.28723.d6, 16365597.
15. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-23. 10.1182/blood-2013-02-486324, 23610374.
16. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006, 134:64-76. 10.1111/j.1365-2141.2006.06108.x, 16803570.
17. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73. 10.1126/scitranslmed.3002842, 21832238.
18. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J 2014, 20:112-8. 10.1097/PPO.0000000000000031, 24667955.
19. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-20. 10.1182/blood-2011-10-384388, 22160384.
20. Leen AM, Sili U, Savoldo B, Jewell AM, Piedra PA, Brenner MK, et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004, 103:1011-9. 10.1182/blood-2003-07-2449, 14525768.
21. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 1998, 9:1419-27. 10.1089/hum.1998.9.10-1419, 9681413.
22. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-55. 9716582.
23. Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CY, Kimbrough S, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998, 91:2925-34. 9531603.
24. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305. 10.1172/JCI32103, 18060041.
25. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 2011, 117:1888-98. 10.1182/blood-2010-10-310599, 21123821.
26. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-28. 10.1182/blood-2011-04-348540, 21849486.
27. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995, 4:73-9. 10.1089/scd.1.1995.4.73, 7633844.
28. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001, 94:228-36. 10.1002/ijc.1457, 11668503.
29. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99:2009-16. 10.1182/blood.V99.6.2009, 11877273.